ROK
55
8
HSY
34
3
NI
75
2
EFX
32
2
SO
55
-2
EL
20
3
BAC
50
-3
ACN
47
-2
COST
58
-2
OXY
40
3
HON
65
-2
QCOM
48
-7
ZTS
47
2
AXP
66
2
UPS
41
-4
PEP
41
6
CVS
48
3
HAS
30
2
HIG
67
4
DAL
80
-4
ROK
55
8
HSY
34
3
NI
75
2
EFX
32
2
SO
55
-2
EL
20
3
BAC
50
-3
ACN
47
-2
COST
58
-2
OXY
40
3
HON
65
-2
QCOM
48
-7
ZTS
47
2
AXP
66
2
UPS
41
-4
PEP
41
6
CVS
48
3
HAS
30
2
HIG
67
4
DAL
80
-4
Financhill
Back

Intellia Therapeutics 10K Form

Sell
18

NTLA
Intellia Therapeutics

Last Price:
14.12
Seasonality Move:
5.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.28M
Cash Flow: $-86.12M
Price / Cash Flow: 0
Annual Sales: $9.46
Price / Book: 1.5

Profitability

EPS (TTM): -5.44000
Net Income (TTM): $-522.28M
Gross Margin: --
Return on Equity: -51.64%
Return on Assets: -42.33%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.73
Quick Ratio: 6.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
18
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?